Stockreport

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

VACCINEX INC  (VCNX) 
PDF ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzhe [Read more]